Zentalis Pharmaceuticals Inc (ZNTL)
11.98
+0.40
(+3.45%)
USD |
NASDAQ |
May 22, 16:00
11.98
0.00 (0.00%)
After-Hours: 20:00
Zentalis Pharmaceuticals Research and Development Expense (Quarterly): 49.58M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 49.58M |
| December 31, 2023 | 51.56M |
| September 30, 2023 | 46.76M |
| June 30, 2023 | 42.68M |
| March 31, 2023 | 48.58M |
| December 31, 2022 | 40.62M |
| September 30, 2022 | 42.18M |
| June 30, 2022 | 43.82M |
| March 31, 2022 | 46.11M |
| December 31, 2021 | 38.44M |
| September 30, 2021 | 54.00M |
| Date | Value |
|---|---|
| June 30, 2021 | 44.77M |
| March 31, 2021 | 38.39M |
| December 31, 2020 | 29.52M |
| September 30, 2020 | 24.67M |
| June 30, 2020 | 17.45M |
| March 31, 2020 | 13.26M |
| December 31, 2019 | 11.87M |
| September 30, 2019 | 10.74M |
| June 30, 2019 | 8.689M |
| March 31, 2019 | 7.089M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
8.689M
Minimum
Jun 2019
54.00M
Maximum
Sep 2021
35.19M
Average
41.40M
Median
Research and Development Expense (Quarterly) Benchmarks
| Revolution Medicines Inc | 118.02M |
| Day One Biopharmaceuticals Inc | 40.21M |
| Perspective Therapeutics Inc | 7.452M |
| Electromed Inc | 0.167M |
| Xtant Medical Holdings Inc | 0.527M |